Detectability of Colorectal Neoplasia With Fluorine-18-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)

immunochemical test (FIT) on same stool samples.Results: There was significant difference in expression of COX-2, MMP-7, B2M, and CKB mRNAs among cancer, AA, and healthy subjects.The 99 percentile of copies of each gene in healthy subjects was used as cutoff value.The specificity of fecal multi-markers RNA panel was 97.3%, while that of FIT was 98.2%.The sensitivity of each assay for CRC was 75.7% for COX-2, 55.9% for MMP-7, 24.3% for B2M, and 28.8% for CKB, respectively, while that of FIT was 66.7%.The sensitivity of fecal B2M and CKB mRNA assay was low, however, fecal B2M plus CKB mRNA assays detected five CRC subjects and five AA subjects with negative results of fecal COX-2 plus MMP-7 mRNA assays.The sensitivity of each assay for CRC was not significantly higher than that of FIT, however, fecal multi-markers RNA panel was significantly higher than that of FIT (84.7% vs. 66.7%,P= 0.003).Among subjects with AA, stage 0, I, or II, who are often cured by endoscopic or surgical resection, fecal multi-markers RNA panel had significantly higher sensitivity than FIT (78.1% vs. 51.0%,P < 0.001).Conclusions: Fecal B2M plus CKB mRNA assays detected ten colorectal advanced neoplasia subjects with negative results of fecal COX-2 plus MMP-7 mRNA assays.These results strongly suggest that fecal multi-markers RNA panel would be a promising approach for CRC screening.